

5-1-2019

## Per- and Polyfluoroalkyl Substances and Bone Mineral Density in Mid-childhood

Shravanthi M. Seshasayee  
*Maine Medical Center*

Rachel Cluett

Lisa B. Rokoff

Sheryl L. Rifas-Shiman

Diane R. Gold

*See next page for additional authors*

Follow this and additional works at: <https://knowledgeconnection.mainehealth.org/mmc>



Part of the [Pediatrics Commons](#)

---

### Recommended Citation

Seshasayee, Shravanthi M.; Cluett, Rachel; Rokoff, Lisa B.; Rifas-Shiman, Sheryl L.; Gold, Diane R.; Coull, Brent; Gordon, Catherine M.; Rosen, Clifford J.; Oken, Emily; Sagiv, Sharon K.; and Fleisch, Abby F., "Per- and Polyfluoroalkyl Substances and Bone Mineral Density in Mid-childhood" (2019). *MaineHealth Maine Medical Center*. 698.

<https://knowledgeconnection.mainehealth.org/mmc/698>

This Poster is brought to you for free and open access by the All MaineHealth at MaineHealth Knowledge Connection. It has been accepted for inclusion in MaineHealth Maine Medical Center by an authorized administrator of MaineHealth Knowledge Connection.

---

## Authors

Shravanthi M. Seshasayee, Rachel Cluett, Lisa B. Rokoff, Sheryl L. Rifas-Shiman, Diane R. Gold, Brent Coull, Catherine M. Gordon, Clifford J. Rosen, Emily Oken, Sharon K. Sagiv, and Abby F. Fleisch



# Per- and Polyfluoroalkyl Substances and Bone Mineral Density in Mid-childhood



Shravanthi M. Seshasayee, BDS MPH,<sup>1\*</sup> Rachel Cluett, MPH,<sup>2</sup> Lisa B. Rokoff, MS,<sup>3</sup> Sheryl L. Rifas-Shiman, MPH,<sup>3</sup> Diane R. Gold, MD MPH,<sup>2, 4</sup> Brent Coull, PhD,<sup>5</sup> Catherine M. Gordon, MD, MS,<sup>6</sup> Clifford J. Rosen, MD,<sup>7</sup> Emily Oken, MD MPH,<sup>3</sup> Sharon K. Sagiv, PhD MPH,<sup>8</sup> Abby F. Fleisch, MD MPH<sup>1, 9</sup>



<sup>1</sup>Center for Outcomes Research and Evaluation, Maine Medical Center Research Institute, <sup>2</sup>Department of Environmental Health, Harvard T. H. Chan School of Public Health, <sup>3</sup>Division of Chronic Disease Research Across the Lifecourse, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, <sup>4</sup>Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, <sup>5</sup>Department of Biostatistics, Harvard T. H. Chan School of Public Health, <sup>6</sup>Division of Adolescent/Young Adult Medicine, Boston Children's Hospital, <sup>7</sup>Center for Clinical & Translational Research, Maine Medical Center Research Institute, <sup>8</sup>Center for Environmental Research and Children's Health (CERCH), School of Public Health, University of California - Berkeley, <sup>9</sup>Pediatric Endocrinology and Diabetes, Maine Medical Center

## Background


- Identifying factors that impair bone accrual during childhood is a critical step toward osteoporosis prevention.
- One potential risk factor not well characterized in childhood is the role of chemicals in the environment.
- Perfluoroalkyl substances (PFASs) are synthetic additives used to make clothing, furniture, and cookware stain repellant and are detectable in almost all US adults<sup>1</sup>.
- PFASs act as PPAR- $\gamma$  agonists,<sup>2</sup> androgen receptor antagonists,<sup>3</sup> and directly intercalate into bone,<sup>4</sup> raising the possibility that they may lead to low bone accrual.
- While two population-based studies in adults have shown associations between PFASs and low areal bone mineral density (aBMD),<sup>5,6</sup> the extent to which PFASs may affect aBMD in children is unknown.

## Objective

Examine the associations of plasma PFAS concentrations with aBMD Z-score in mid-childhood (mean 7.9 years)

## Study population (Project Viva)

Boston-area pregnant women enrolled 1999-2002 into the prospective Project Viva birth cohort



## Methods

### Exposure (PFASs):

- Perfluorooctanoate (**PFOA**), perfluorooctane sulfonate (**PFOS**), perfluorodecanoate (**PFDA**), perfluorohexane sulfonate (**PFHxS**), 2-(N-methyl-perfluorooctane sulfonamido) acetate (**MeFOSAA**), perfluorononanoate (**PFNA**)

- Measured in plasma by CDC staff using on-line solid-phase extraction with isotope dilution high performance liquid chromatography mass spectrometry

### Outcome (aBMD Z-score):

- Total body (excluding the skull) aBMD measured via dual-energy X-ray absorptiometry (DXA)

- Analyzed DXA data with pediatric software (Hologic, version 12.6) and used U.S. national reference data to derive age-, sex-, race-, and height-adjusted aBMD Z-scores.<sup>7</sup>

### Statistical analyses:

- Used linear regression to examine associations of each PFAS with aBMD Z-score separately in single-PFAS models, and mutually adjusted with other PFASs in a multi-PFAS model
- Examined association between the PFAS mixture and aBMD Z-score via weighted quantile sum (WQS) regression. WQS generates a composite mixture index for each participant, assigning each PFAS within the mixture a weight reflecting:
  - Strength of its association with aBMD Z-score
  - Collinearity with other PFASs within mixture

- Log<sub>2</sub> transformed plasma PFAS concentrations for linear associations with outcome

- Covariates in final models were maternal age, education, annual household income, census tract median household income, and child age, sex, race/ethnicity, and dairy intake, physical activity, and year of blood draw

- No evidence for effect modification by sex, so present results without an interaction term

## Results

Table 1. Participant characteristics overall and by PFOA plasma concentration

	Quantiles of PFOA <sup>a</sup> plasma concentration				
	Overall n=576	Q1 n=145	Q2 n=147	Q3 n=140	Q4 n=144
Mean $\pm$ SD or n (%)					
<b>Maternal characteristics</b>					
Maternal age at enrollment (years)	31.8 $\pm$ 5.7	29.8 $\pm$ 6.5	31.6 $\pm$ 5.9	32.7 $\pm$ 5.0	33.1 $\pm$ 4.5
College graduate (%)	364 (64)	59 (41)	89 (61)	101 (73)	115 (80)
Individual household income (%)					
< \$40,000/year	85 (16)	39 (30)	20 (14)	15 (11)	11 (8)
\$40,001-\$70,000/year	89 (16)	25 (19)	23 (17)	22 (16)	19 (13)
> \$70,000/year	369 (68)	65 (51)	96 (69)	98 (73)	110 (79)
Census tract median household income (\$10,000/year)	62.7 $\pm$ 23.7	53.5 $\pm$ 21.0	60.4 $\pm$ 23.2	64.7 $\pm$ 21.0	72.4 $\pm$ 25.5
<b>Child characteristics</b>					
Age (years)	7.9 $\pm$ 0.8	8.2 $\pm$ 1.0	8.0 $\pm$ 0.8	7.8 $\pm$ 0.7	7.7 $\pm$ 0.6
Female (%)	280 (49)	73 (50)	73 (50)	101 (45)	71 (49)
Race/ethnicity (%)					
White	328 (57)	37 (26)	80 (54)	94 (68)	117 (81)
Black	129 (23)	66 (46)	32 (22)	21 (15)	10 (7)
Other	117 (20)	41 (28)	35 (24)	24 (17)	17 (12)
Dairy intake (servings/wk)	2.2 $\pm$ 1.5	2.0 $\pm$ 1.5	2.2 $\pm$ 1.5	2.3 $\pm$ 1.6	2.4 $\pm$ 1.5
Physical activity (hrs/wk)	1.9 $\pm$ 1.4	1.9 $\pm$ 1.5	1.7 $\pm$ 1.3	1.9 $\pm$ 1.2	1.9 $\pm$ 1.5
aBMD Z-score	-0.86 $\pm$ 0.77	-0.73 $\pm$ 0.73	-0.81 $\pm$ 0.84	-0.95 $\pm$ 0.73	-0.93 $\pm$ 0.78

<sup>a</sup> PFOA quartile minimum and maximum values: <0.1 (LOD)-3.0 ng/mL for Q1, 3.1-4.4 ng/mL for Q2, 4.5-6.1 ng/mL for Q3, and 6.2-14.3 ng/mL for Q4

Table 2. Plasma PFAS concentration distributions and correlations

	Plasma PFAS concentrations (ng/mL)					
	PFOA	PFOS	PFDA	PFHxS	MeFOSAA	PFNA
<b>Median (IQR)</b>	4.4 (3.2)	6.4 (5.6)	0.3 (0.3)	1.9 (2.3)	0.3 (0.5)	1.5 (1.2)
<b>5<sup>th</sup> percentile</b>	1.9	2.1	< LOD <sup>a</sup>	0.6	< LOD <sup>a</sup>	0.7
<b>95<sup>th</sup> percentile</b>	9.8	18.7	0.7	14.7	1.9	5.1
<b>Detection frequency (%)</b>	99.5	99.5	88.4	99.5	65.6	99.5
<b>Spearman correlation coefficients</b>						
<b>PFOA</b>	1.00					
<b>PFOS</b>	0.79	1.00				
<b>PFDA</b>	0.69	0.59	1.00			
<b>PFHxS</b>	0.60	0.67	0.34	1.00		
<b>MeFOSAA</b>	0.50	0.63	0.32	0.37	1.00	
<b>PFNA</b>	0.43	0.35	0.57	0.13	0.22	1.00

<sup>a</sup> Limit of detection (LOD) was 0.1 ng/mL for all PFASs

## Strengths and Limitations

### Strengths

- Among the first studies to evaluate role of toxicants on bone health in childhood
- PFAS concentrations typical for US population during peak production
- Used WQS regression to assess exposure to PFAS mixture

### Limitations

- High SES cohort limits generalizability
- Cross sectional analysis, so unable to assess mediation by BMI or pubertal status

## Conclusions

- Higher exposure to PFASs was associated with lower aBMD Z-scores in children.
- Lower exposures to environmental toxicants such as PFASs may improve childhood bone accrual and optimize lifelong skeletal health.

## Acknowledgements

We thank the staff and participants of Project Viva for their support. We also thank CDC staff for conducting PFAS measurements.

## References

- Calafat AM, Kuklenyik Z, Reidy JA, Caudill SP, Tully JS, Needham LL. 2007. Serum concentrations of 11 polyfluoroalkyl compounds in the U.S. Population: Data from the National Health and Nutrition Examination Survey (NHANES). Environ Sci Technol 41:2237-2242.
- Yamamoto J, Yamane T, Oishi Y, Kobayashi-Hattori K. 2015. Perfluorooctanoic acid binds to peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation in 3T3-L1 adipocytes. Biosci Biotechnol Biochem 79:636-639.
- Kjeldsen LS, Bonefeld-Jorgensen EC. 2013. Perfluorinated compounds affect the function of sex hormone receptors. Environ Sci Pollut Res Int 20:8031-8044.
- Koskela A, Koponen J, Lehenkari P, Viluksela M, Korkalainen M, Tuukkanen J. 2017. Perfluoroalkyl substances in human bone: Concentrations in bones and effects on bone cell differentiation. Sci Rep 7:6841.
- Khalil N, Chen A, Lee M, Czerwinski SA, Ebert JR, DeWitt JC, et al. 2016. Association of perfluoroalkyl substances, bone mineral density, and osteoporosis in the U.S. Population in NHANES 2009–2010. Environ Health Perspect 124:81-87.
- Lin LY, Wen LL, Su TC, Chen PC, Lin CY. 2014. Negative association between serum perfluorooctane sulfate concentration and bone mineral density in U.S. premenopausal women: NHANES, 2005-2008. J Clin Endocrinol Metab 99:2173-2180.
- Zemel BS, Kalkwarf HJ, Gilsanz V, Lappe JM, Oberfield S, Shepherd JA, et al. 2011. Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: Results of the bone mineral density in childhood study. J Clin Endocrinol Metab 96:3160-3169.

*The authors have no financial relationships to disclose or conflicts of interest to resolve.*

Figure 1. Single and multi-PFAS models showing adjusted associations of individual PFAS plasma concentrations with aBMD Z-score





Figure 2. Weights assigned to individual PFASs within the WQS composite index



Each IQR increment in the WQS index was associated with a -0.16 lower aBMD Z-score (95% CI: -0.28, -0.04).